Additional Market Authorizations for AMW’s Goserelin Implant for the Treatment of Hormone-Dependent Tumors in the EU and Central America
AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced that its goserelin implant has received market authorization in one country each in the European Union and Central America. . AMW’s goserelin implant is the only generic implant version approved to date for AstraZeneca’s branded Zoladex®1. Goserelin enables symptomatic therapy of hormone-dependent tumors, such as prostate or breast cancer, as well as certain gynecological disorders. AMW’s goserelin implant is now available to patients in around 30 countries worldwide as a cost-effective alternative therapy.
read more